

Appendix 4D

Half-Year Consolidated Financial Report

Introduced 1/1/2003.

Name of Entity	OBJ LIMITED
ABN	72 056 482 636
Financial Period Ended	31 DECEMBER 2014
Previous Corresponding Reporting Period	31 DECEMBER 2013

Results for Announcement to the Market

	\$'000	Percentage increase /(decrease) over previous corresponding period
Revenue	1,086	Up 49%
Loss for the period	(809)	Down 12%
Loss attributable to members of the parent entity	(809)	Down 12%
Dividends (distributions)	Amount per security	Franked amount per security
Final Dividend	Nil	Nil
Interim Dividend	Nil	Nil
Previous corresponding period *	Nil	Nil
Record date for determining entitlements to the dividends (if any)	N/A	
Brief explanation of any of the figures reported above necessary to enable the figures to be understood:		
Refer to the Review of Operations section of the Directors' Report included in Attachment 1.		

The half-year consolidated financial report is to be read in conjunction with the most recent annual financial report.

Dividends

Date the dividend is payable	N/A
Record date to determine entitlement to the dividend	N/A
Amount per security	N/A
Total dividend	N/A
Amount per security of foreign sourced dividend or distribution	N/A
Details of any dividend reinvestment plans in operation	N/A
The last date for receipt of an election notice for participation in any dividend reinvestment plans	N/A

NTA Backing

	Current Period	Previous corresponding period
Net tangible asset backing per ordinary security	\$0.003	\$0.003

Other Significant Information Needed by an Investor to Make an Informed Assessment of the Entity's Financial Performance and Financial Position

Refer to the Review of Operations section of the Directors' Report included in Attachment 1.

Commentary on the Results for the Period

The earnings per security and the nature of any dilution aspects :

Refer to the Statement of Comprehensive Income in Attachment 1.

Returns to shareholders including distributions and buy backs :

N/A

Significant features of operating performance :

Refer to the Review of Operations section of the Directors' Report included in Attachment 1.

The results of segments that are significant to an understanding of the business as a whole:

Refer to the Review of Operations section of the Directors' Report included in Attachment 1.

Discussion of trends in performance :

Refer to the Review of Operations section of the Directors' Report included in Attachment 1.

Any other factor which has affected the results in the period or which are likely to affect results in the future, including those where the effect could not be quantified:

N/A

Control Gained Over Entities Having Material Effect

Name of entity (or group of entities)	N/A
Date control gained	N/A
Consolidated profit / (loss) from ordinary activities since the date in the current period on which control was acquired	N/A
Profit / (loss) from ordinary activities of the controlled entity (or group of entities) for the whole of the previous corresponding period	N/A

Loss of Control Gained Over Entities Having Material Effect

Name of entity (or group of entities)	N/A
Date control lost	N/A
Consolidated profit / (loss) from ordinary activities for the current period to the date of loss of control ('\$000)	N/A
Profit / (loss) from ordinary activities of the controlled entity (or group of entities) while controlled for the whole of the previous corresponding period ('\$000)	N/A

Details of Associates and Joint Venture Entities

Name of Entity	Percentage Held		Share of Net Profit	
	Current Period	Previous Period	Current Period	Previous Period
N/A				
Aggregate Share of Net Profits				

Audit/Review Status

This half-year consolidated financial report is based on accounts to which one of the following applies: (Tick one)			
The accounts have been audited		The accounts have been subject to review	X
The accounts are in the process of being audited or subject to review		The accounts have not yet been audited or reviewed	
If the accounts have not yet been audited or subject to review and are likely to be subject to dispute or qualification, a description of the likely dispute or qualification:			
N/A			
If the accounts have been audited or subject to review and are subject to dispute or qualification, a description of the dispute or qualification:			
N/A			

Attachments Forming Part of Appendix 4D

Attachment #	Details
1	Interim Consolidated Financial Report

Signed By (Director)	
Print Name	Glyn Denison
Date	25 th February 2015

OBJ LIMITED
A.B.N. 72 056 482 636

DIRECTOR'S REPORT

The directors present their consolidated financial statements on the results of OBJ Limited and its controlled entities for the financial half-year ended 31 December 2014.

Directors

The names of directors in office at any time during or since the end of the period are:

Mr Glyn Gregory Horne Denison
Mr Jeffrey David Edwards
Dr Christopher John Quirk

Directors have been in office since the start of the financial year to the date of this report.

Review of Operations

The half-year to 31 December 2014 was one of the most meaningful in the Company's history.

The licensing and launch of the first product containing OBJ technology, the signing of agreements with COTY and progress with BodyGuard have all been significant accomplishments during the period. The high level of take up of the Company's December 2014 Options is seen as a vote of confidence in the Company and provides a healthy cash balance to meet the new challenges of 2015.

P&G Product Launch

The launch of the first commercial product containing the Company's technology by the world's largest consumer products company was a significant event. This was the culmination of many years of work with P&G's scientific and marketing teams.

To have P&G select their most prestigious brand to launch the first OBJ products in their most critical-growth markets of Asia and China provides substantial validation of the Company's technologies.

P&G Work Plans

The multi-product Product Development Agreement (PDA), announced in April 2014, had three programs of work attached. The first has been launched in selected markets in the form of the SK-II magnetic eye wand with the remaining two moving through their respective development pathways. Following the success of the SK-II launch and the high level of customer interest, two additional P&G brands have been added to programs of work under the original PDA.



OBJ LIMITED
A.B.N. 72 056 482 636

DIRECTOR'S REPORT (continued)

Review of Operations (continued)

Coty Licence and Development Term Sheet

The signing of a License and Development Term Sheet with the COTY group was another vote of confidence. The COTY agreement utilises the Company's Powered Dermaportation technology and is an example of how the Company can potentially license more than one party in the same commercial space.

BodyGuard Exclusive Evaluation Agreement

Progress with the Company's internally developed BodyGuard project exceeded expectations during the half-year with the signing of an Exclusive Evaluation Agreement with P&G's New Business Creation Group (NBC). Under this Agreement, P&G will undertake detailed marketing and sales research with the Company to undertake a human clinical trial.



P&G and OBJ will then share the results of each program and P&G will have an exclusive but limited time period to negotiate a commercial arrangement with OBJ with a view to creating a new brand in P&G's Life Style business. The Company had been in initial discussions with a number of other major corporations with an interest in the BodyGuard opportunity. P&G's

early move to secure exclusive access is another vote of confidence in the Company's technologies.

Expanding Internal Programs

BodyGuard was originally established to create value-added products utilising the Company's technologies, with a view to seeking distribution partners for more developed and high value products, rather than out-licensing the technology at an early stage.

Following the success of this strategy in BodyGuard, the Company expanded its Internal Development team with Mr Phillip Russell joining the OBJ scientific team to progress two additional value-added projects in Surface Penetration/Hygiene and e-Skin, the e-commerce version of the programmable Dermaportation wand technology.

The Company also continues to grow its internal and scientific resources and to expand its capabilities in order to meet partner needs. A new high throughput Mass Spectrometer has been commissioned to increase OBJ's laboratory capabilities in both sensitivity and throughput. The Company is currently negotiating to secure additional office and laboratory space at its Leederville, Western Australia facility.



OBJ LIMITED
A.B.N. 72 056 482 636

DIRECTOR'S REPORT (*continued*)

Auditor's Independence Declaration

In accordance with the Audit Independence requirements of the Corporations Act 2001, the directors have received and are satisfied with the "Audit Independence Declaration" provided by OBJ Limited external auditors RSM Bird Cameron Partners. The Audit Independence Declaration is included within this consolidated financial report.

Signed in accordance with a resolution of the board of directors.


Glyn Denison
Director

Dated this 25th day of February 2015

RSM Bird Cameron Partners
8 St Georges Terrace Perth WA 6000
GPO Box R1253 Perth WA 6844
T +61 8 9261 9100 F +61 8 9261 9101
www.rsmi.com.au


AUDITOR'S INDEPENDENCE DECLARATION

As lead auditor for the review of the financial report of OBJ Limited for the half-year ended 31 December 2014, I declare that, to the best of my knowledge and belief, there have been no contraventions of:

- (i) the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
- (ii) any applicable code of professional conduct in relation to the review.

RSM Bird Cameron Partners

RSM BIRD CAMERON PARTNERS



J A KOMNINOS
Partner

Perth, WA
Dated: 25 February 2015

**CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE HALF-YEAR ENDED 31 DECEMBER 2014**

	31 Dec. 2014 \$	31 Dec. 2013 \$
Revenue	1,086,432	727,570
Net foreign exchange gains	23,528	20,652
Borrowing costs	(8,338)	(9,500)
Depreciation expenses	(14,006)	(11,652)
Administration fees	(121,837)	(83,751)
Auditor's remuneration	(18,405)	(9,000)
Consultants and consultants benefits expenses	(470,396)	(592,574)
Directors and employees benefits expenses	(585,180)	(461,110)
Insurance	(11,160)	(10,894)
Legal costs	(49,675)	(45,671)
Materials and requisites	(63,045)	(9,649)
Occupancy expenses	(57,444)	(45,931)
Patent fees	(67,565)	(44,660)
Product design expenses	(181,027)	(126,960)
Product presentation expenses	(23,493)	--
Public relations	(49,093)	(46,068)
Share register maintenance	(92,452)	(49,655)
Travel and accommodation	(71,273)	(85,493)
Other expenses	(34,684)	(33,674)
Loss before income tax	(809,113)	(918,020)
Income tax	--	--
Loss for the period	(809,113)	(918,020)
Other comprehensive income	--	--
Total comprehensive loss for the period	(809,113)	(918,020)
Loss attributable to:		
Members of the parent entity	(809,113)	(918,020)
	Cents	Cents
Basic and diluted losses per share (cents per share)	(0.05)	(0.07)

The above consolidated statement of comprehensive income should be read in conjunction with the accompanying notes.

**CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2014**

	Note	31 Dec. 2014 \$	30 Jun. 2014 \$
CURRENT ASSETS			
Cash and cash equivalents		4,532,285	4,025,038
Trade and other receivables		692,623	157,714
TOTAL CURRENT ASSETS		<u>5,224,908</u>	<u>4,182,752</u>
NON CURRENT ASSETS			
Plant and equipment		187,614	107,548
TOTAL NON CURRENT ASSETS		<u>187,614</u>	<u>107,548</u>
TOTAL ASSETS		<u>5,412,522</u>	<u>4,290,300</u>
CURRENT LIABILITIES			
Trade and other payables		564,765	227,866
Borrowings		189,000	233,250
TOTAL CURRENT LIABILITIES		<u>753,765</u>	<u>461,116</u>
TOTAL LIABILITIES		<u>753,765</u>	<u>461,116</u>
NET ASSETS		<u>4,658,757</u>	<u>3,829,184</u>
EQUITY			
Issued capital	2	25,218,468	23,688,809
Reserves	3	2,100,401	1,991,374
Accumulated losses		(22,660,112)	(21,850,999)
TOTAL EQUITY		<u>4,658,757</u>	<u>3,829,184</u>

*The above consolidated statement of financial position
should be read in conjunction with the accompanying notes.*

**CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE HALF-YEAR ENDED 31 DECEMBER 2014**

	Issued Capital	Share Based Payments Reserve	Accumulated Losses	Total
	\$	\$	\$	\$
Balance at 1 July 2013	21,204,293	1,661,481	(19,645,645)	3,220,129
Total comprehensive loss for the period	--	--	(918,020)	(918,020)
Shares issued during the period	2,460,859	--	--	2,460,859
Options issued during the period	--	160,000	--	160,000
Performance rights issued during the period	--	97,356	--	97,356
Transaction costs	(165,985)	--	--	(165,985)
Balance at 31 December 2013	<u>23,499,167</u>	<u>1,918,837</u>	<u>(20,563,665)</u>	<u>4,854,339</u>
Balance at 1 July 2014	23,688,809	1,991,374	(21,850,999)	3,829,184
Total comprehensive loss for the period	--	--	(809,113)	(809,113)
Shares issued during the period	1,529,659	--	--	1,529,659
Performance rights issued during the period	--	109,027	--	109,027
Transaction costs	--	--	--	--
Balance at 31 December 2014	<u>25,218,468</u>	<u>2,100,401</u>	<u>(22,660,112)</u>	<u>4,658,757</u>

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

**CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE HALF-YEAR ENDED 31 DECEMBER 2014**

	31 Dec. 2014 \$	31 Dec. 2013 \$
Cash flows from operating activities		
Receipts from customers	574,950	649,505
Payments to suppliers and employees	(1,591,145)	(1,443,675)
Interest received	102,195	41,436
Borrowing costs	(2,588)	(2,500)
	<hr/>	<hr/>
Net cash used in operating activities	(916,588)	(755,234)
	<hr/>	<hr/>
Cash flows from investing activities		
Payment for plant and equipment	(94,072)	(9,614)
	<hr/>	<hr/>
Net cash used in investing activities	(94,072)	(9,614)
	<hr/>	<hr/>
Cash flows from financing activities		
Proceeds from issue of shares and options	1,479,659	2,460,859
Transaction costs from issue of shares and options	--	(165,985)
Other	14,720	--
	<hr/>	<hr/>
Net cash provided by financing activities	1,494,379	2,294,874
	<hr/>	<hr/>
Net increase in cash and cash equivalents held	483,719	1,530,026
Cash and cash equivalents at the beginning of the financial period	4,025,038	3,432,804
Effect of exchange rate changes on cash holdings	23,528	20,652
	<hr/>	<hr/>
Cash and cash equivalents at the end of the financial period	4,532,285	4,983,482

*The above consolidated statement of cash flows
should be read in conjunction with the accompanying notes.*

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1: BASIS OF PREPARATION

The half-year consolidated financial report is a general purpose financial report prepared in accordance with the requirements of the *Corporations Act 2001* and Accounting Standard AASB 134: Interim Financial Reporting. Compliance with AASB 134 ensures that the financial report and notes also comply with International Financial Reporting Standard IAS 34: Interim Financial Reporting.

It is recommended that this consolidated financial report be read in conjunction with the annual financial report for the year ended 30 June 2014 and any public announcements made by OBJ Limited and its controlled entities during the half-year in accordance with the continuous disclosure requirements arising under the *Corporations Act 2001*.

The half-year consolidated financial report does not include full disclosures of the type normally included in annual financial reports.

Except for cash flow information, the half-year consolidated financial report has been prepared on an accruals basis and is based on historical costs.

The accounting policies have been consistently applied by the Consolidated Entity and are consistent with those in the 30 June 2014 annual financial report, except in relation to the matters disclosed below:

New and Revised Accounting Standards and Interpretations

The Consolidated Entity has adopted all of the new and revised Accounting Standards and Interpretations issued by the Australian Accounting Standards Board that are mandatory for the current reporting period. The adoption of these new and revised Accounting Standards and Interpretations has not resulted in a significant or material change to the Consolidated Entity's accounting policies.

Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted by the Consolidated Entity.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

		Consolidated	
		31 Dec. 2014	30 Jun. 2014
		\$	\$
NOTE 2: ISSUED CAPITAL			
(a) Issued capital			
1,649,587,813 Ordinary shares fully paid (30/06/14: 1,473,955,360)		25,218,468	23,688,809
(b) Movements in ordinary share capital		Number of Shares	\$
01/07/2014	Opening balance	1,473,955,360	23,688,809
03/07/2014	Conversion of listed options	8,000	80
14/07/2014	Conversion of listed options	2,999,481	29,995
28/07/2014	Conversion of listed options	1,000,000	10,000
29/07/2014	Conversion of listed options	4,518	45
30/07/2014	Conversion of listed options	34,560	346
31/07/2014	Conversion of listed options	3,333,503	33,335
01/08/2014	Conversion of listed options	108,000	1,080
07/08/2014	Conversion of listed options	40,000	400
08/08/2014	Conversion of listed options	34,770	348
11/08/2014	Conversion of listed options	800,000	8,000
13/08/2014	Conversion of listed options	100,000	1,000
14/08/2014	Conversion of listed options	240,000	2,400
15/08/2014	Conversion of listed options	18,560	186
19/08/2014	Conversion of listed options	13,600	136
20/08/2014	Conversion of listed options	163,333	1,633
21/08/2014	Conversion of listed options	240,000	2,400
22/08/2014	Conversion of listed options	9,630	96
25/08/2014	Conversion of listed options	4,800	48
28/08/2014	Conversion of listed options	98,534	985
04/09/2014	Conversion of listed options	1,008,000	10,080
05/09/2014	Conversion of listed options	917,981	9,180
10/09/2014	Conversion of listed options	45,000	450
12/09/2014	Conversion of listed options	242,435	2,424
17/09/2014	Conversion of listed options	200,000	2,000
19/09/2014	Conversion of listed options	173,334	1,733
22/09/2014	Conversion of listed options	34,560	346
03/10/2014	Conversion of listed options	892,054	8,920
06/10/2014	Conversion of listed options	8,000	80
06/10/2014	Conversion of convertible notes	16,666,667	50,000
10/10/2014	Pursuant to the satisfaction of performance milestone 3	11,000,000	--
10/10/2014	Conversion of listed options	300,000	3,000
14/10/2014	Conversion of listed options	1,750,000	17,500
16/10/2014	Conversion of listed options	785,983	7,859
16/10/2014	Conversion of listed options	2,122,400	21,224
20/10/2014	Conversion of listed options	116,667	1,167
21/10/2014	Conversion of listed options	560,000	5,600
23/10/2014	Conversion of listed options	400,000	4,000
27/10/2014	Conversion of listed options	76,007	760
29/10/2014	Conversion of listed options	50,000	500
04/11/2014	Conversion of listed options	56,430	564
05/11/2014	Conversion of listed options	200,000	2,000
06/11/2014	Conversion of listed options	1,646,667	16,467
07/11/2014	Conversion of listed options	6,564,711	65,647
12/11/2014	Conversion of listed options	3,653,208	36,532
13/11/2014	Conversion of listed options	10,334	103
18/11/2014	Conversion of listed options	430,705	4,307
19/11/2014	Conversion of listed options	51,724	517

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
NOTE 2: ISSUED CAPITAL (continued)**(b) Movements in ordinary share capital (continued)**

		Number of Shares	\$
20/11/2014	Conversion of listed options	160,000	1,600
21/11/2014	Conversion of listed options	200,000	2,000
24/11/2014	Conversion of listed options	24,000	240
25/11/2014	Conversion of listed options	1,237,120	12,371
26/11/2014	Conversion of listed options	350,166	3,502
27/11/2014	Conversion of listed options	484,124	4,842
28/11/2014	Conversion of listed options	2,201,000	22,010
01/12/2014	Conversion of listed options	49,894	499
02/12/2014	Conversion of listed options	2,332,000	23,320
03/12/2014	Conversion of listed options	676,934	6,770
04/12/2014	Conversion of listed options	70,315	703
05/12/2014	Conversion of listed options	1,675,016	16,750
08/12/2014	Conversion of listed options	6,212,426	62,125
09/12/2014	Conversion of listed options	1,486,404	14,864
10/12/2014	Conversion of listed options	5,515,168	55,152
11/12/2014	Conversion of listed options	11,626,790	116,268
12/12/2014	Conversion of listed options	1,447,095	14,471
16/12/2014	Conversion of listed options	2,019,783	20,198
17/12/2014	Conversion of listed options	2,746,470	27,465
18/12/2014	Conversion of listed options	2,345,827	23,459
19/12/2014	Conversion of listed options	2,161,544	21,616
22/12/2014	Conversion of listed options	1,527,816	15,278
23/12/2014	Conversion of listed options	8,981,411	89,814
24/12/2014	Conversion of listed options	11,836,633	118,366
29/12/2014	Conversion of listed options	31,137,392	311,374
30/12/2014	Conversion of listed options	7,632,330	76,323
31/12/2014	Conversion of listed options	10,280,639	102,806
	Less: costs associated with the issue of shares		--
31/12/2014	Closing balance	<u>1,649,587,813</u>	<u>25,218,468</u>

NOTE 3: RESERVES

	Consolidated	
	31 Dec. 2014	30 Jun. 2014
	\$	\$
(a) Composition		
Share based payments reserve	<u>2,100,401</u>	<u>1,991,374</u>

The share based payments reserve records items recognised as expenses on valuation of director/ employee/consultant share options and performance rights.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

NOTE 3: RESERVES (continued)

(b) Movements in options and performance rights were as follows:

Date	Details	Number of Performance Rights	Number of Options Listed	Number of Options Unlisted	Exercise Price	Fair Value of Options / Perf. Rights Issued	Expiry Date
01/07/14	Opening Balance	11,000,000	150,386,983	--	--	\$1,991,374	--
03/07/14	Conversion of listed options	--	(8,000)	--	\$0.01	--	31/12/2014
14/07/14	Conversion of listed options	--	(2,999,481)	--	\$0.01	--	31/12/2014
28/07/14	Conversion of listed options	--	(1,000,000)	--	\$0.01	--	31/12/2014
29/07/14	Conversion of listed options	--	(4,518)	--	\$0.01	--	31/12/2014
30/07/14	Conversion of listed options	--	(34,560)	--	\$0.01	--	31/12/2014
31/07/14	Conversion of listed options	--	(3,333,503)	--	\$0.01	--	31/12/2014
01/08/14	Conversion of listed options	--	(108,000)	--	\$0.01	--	31/12/2014
07/08/14	Conversion of listed options	--	(40,000)	--	\$0.01	--	31/12/2014
08/08/14	Conversion of listed options	--	(34,770)	--	\$0.01	--	31/12/2014
11/08/14	Conversion of listed options	--	(800,000)	--	\$0.01	--	31/12/2014
13/08/14	Conversion of listed options	--	(100,000)	--	\$0.01	--	31/12/2014
14/08/14	Conversion of listed options	--	(240,000)	--	\$0.01	--	31/12/2014
15/08/14	Conversion of listed options	--	(18,560)	--	\$0.01	--	31/12/2014
19/08/14	Conversion of listed options	--	(13,600)	--	\$0.01	--	31/12/2014
20/08/14	Conversion of listed options	--	(163,333)	--	\$0.01	--	31/12/2014
21/08/14	Conversion of listed options	--	(240,000)	--	\$0.01	--	31/12/2014
22/08/14	Conversion of listed options	--	(9,630)	--	\$0.01	--	31/12/2014
25/08/14	Conversion of listed options	--	(4,800)	--	\$0.01	--	31/12/2014
28/08/14	Conversion of listed options	--	(98,534)	--	\$0.01	--	31/12/2014
04/09/14	Conversion of listed options	--	(1,008,000)	--	\$0.01	--	31/12/2014
05/09/14	Conversion of listed options	--	(917,981)	--	\$0.01	--	31/12/2014
10/09/14	Conversion of listed options	--	(45,000)	--	\$0.01	--	31/12/2014
12/09/14	Conversion of listed options	--	(242,435)	--	\$0.01	--	31/12/2014
17/09/14	Conversion of listed options	--	(200,000)	--	\$0.01	--	31/12/2014
19/09/14	Conversion of listed options	--	(173,334)	--	\$0.01	--	31/12/2014
22/09/14	Conversion of listed options	--	(34,560)	--	\$0.01	--	31/12/2014
03/10/14	Conversion of listed options	--	(892,054)	--	\$0.01	--	31/12/2014
06/10/14	Conversion of listed options	--	(8,000)	--	\$0.01	--	31/12/2014
10/10/14	Pursuant to the satisfaction of performance milestone 3	(11,000,000)	--	--	--	--	09/12/2014
10/10/14	Add: value of performance rights carried forward from 30/06/14 (refer Note 7)	--	--	--	--	\$23,235	09/12/2014
10/10/14	Conversion of listed options	--	(300,000)	--	\$0.01	--	31/12/2014
14/10/14	Conversion of listed options	--	(1,750,000)	--	\$0.01	--	31/12/2014
16/10/14	Conversion of listed options	--	(785,983)	--	\$0.01	--	31/12/2014
16/10/14	Conversion of listed options	--	(2,122,400)	--	\$0.01	--	31/12/2014
20/10/14	Conversion of listed options	--	(116,667)	--	\$0.01	--	31/12/2014
21/10/14	Conversion of listed options	--	(560,000)	--	\$0.01	--	31/12/2014
23/10/14	Conversion of listed options	--	(400,000)	--	\$0.01	--	31/12/2014
27/10/14	Conversion of listed options	--	(76,007)	--	\$0.01	--	31/12/2014
29/10/14	Conversion of listed options	--	(50,000)	--	\$0.01	--	31/12/2014
04/11/14	Conversion of listed options	--	(56,430)	--	\$0.01	--	31/12/2014
05/11/14	Conversion of listed options	--	(200,000)	--	\$0.01	--	31/12/2014
06/11/14	Conversion of listed options	--	(1,646,667)	--	\$0.01	--	31/12/2014
07/11/14	Conversion of listed options	--	(6,564,711)	--	\$0.01	--	31/12/2014
12/11/14	Conversion of listed options	--	(3,653,208)	--	\$0.01	--	31/12/2014
13/11/14	Conversion of listed options	--	(10,334)	--	\$0.01	--	31/12/2014
18/11/14	Conversion of listed options	--	(372,675)	--	\$0.01	--	31/12/2014
18/11/14	Conversion of listed options	--	(58,030)	--	\$0.01	--	31/12/2014
19/11/14	Conversion of listed options	--	(51,724)	--	\$0.01	--	31/12/2014
20/11/14	Conversion of listed options	--	(160,000)	--	\$0.01	--	31/12/2014
21/11/14	Conversion of listed options	--	(200,000)	--	\$0.01	--	31/12/2014
24/11/14	Conversion of listed options	--	(24,000)	--	\$0.01	--	31/12/2014
25/11/14	Conversion of listed options	--	(1,237,120)	--	\$0.01	--	31/12/2014
26/11/14	Conversion of listed options	--	(350,166)	--	\$0.01	--	31/12/2014
27/11/14	Conversion of listed options	--	(484,124)	--	\$0.01	--	31/12/2014
28/11/14	Conversion of listed options	--	(2,201,000)	--	\$0.01	--	31/12/2014
01/12/14	Conversion of listed options	--	(49,894)	--	\$0.01	--	31/12/2014

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (*continued*)

NOTE 3: RESERVES (*continued*)

(b) Movements in options and performance rights (*continued*)

	Performance Rights	Listed	Unlisted	Price	Options / Perf. Rights Issued	Date
02/12/14	Conversion of listed options	--	(2,332,000)	--	\$0.01	-- 31/12/2014
03/12/14	Conversion of listed options	--	(676,934)	--	\$0.01	-- 31/12/2014
04/12/14	Conversion of listed options	--	(70,315)	--	\$0.01	-- 31/12/2014
05/12/14	Conversion of listed options	--	(1,675,016)	--	\$0.01	-- 31/12/2014
08/12/14	Conversion of listed options	--	(6,212,426)	--	\$0.01	-- 31/12/2014
09/12/14	Conversion of listed options	--	(1,486,404)	--	\$0.01	-- 31/12/2014
10/12/14	Conversion of listed options	--	(5,515,168)	--	\$0.01	-- 31/12/2014
11/12/14	Conversion of listed options	--	(11,626,790)	--	\$0.01	-- 31/12/2014
12/12/14	Conversion of listed options	--	(1,447,095)	--	\$0.01	-- 31/12/2014
16/12/14	Conversion of listed options	--	(2,019,783)	--	\$0.01	-- 31/12/2014
17/12/14	Conversion of listed options	--	(2,746,470)	--	\$0.01	-- 31/12/2014
18/12/14	Conversion of listed options	--	(2,345,827)	--	\$0.01	-- 31/12/2014
19/12/14	Conversion of listed options	--	(2,161,544)	--	\$0.01	-- 31/12/2014
22/12/14	Conversion of listed options	--	(1,527,816)	--	\$0.01	-- 31/12/2014
22/12/14	Pursuant to shareholder approval on 28 Nov. 2014	45,000,000	--	--	\$1,534,500	28/11/2017
22/12/14	Pursuant to directors resolution	37,000,000	--	--	\$1,207,434	28/11/2017
23/12/14	Conversion of listed options	--	(8,981,411)	--	\$0.01	-- 31/12/2014
24/12/14	Conversion of listed options	--	(11,836,633)	--	\$0.01	-- 31/12/2014
29/12/14	Conversion of listed options	--	(31,137,392)	--	\$0.01	-- 31/12/2014
30/12/14	Conversion of listed options	--	(7,632,330)	--	\$0.01	-- 31/12/2014
31/12/14	Conversion of listed options	--	(10,280,639)	--	\$0.01	-- 31/12/2014
31/12/14	Listed options expired	--	(1,012,174)	--	\$0.01	-- 31/12/2014
31/12/14	Less: value of performance rights carried forward from 31/12/14 (refer Note 7)	--	--	--	(\$2,656,142)	--
31/12/14	Closing Balance	82,000,000	1,409,023	--	\$2,100,401	

NOTE 4: DIVIDENDS

There have been no dividends declared or recommended and no distributions made to shareholders or other persons during the period.

NOTE 5: SEGMENT INFORMATION

The Company has considered the requirements of AASB8 – Operating Segments and has identified its operating segments based on the internal reports that are reviewed and used by the board of directors (chief operating decision makers) in assessing performance and determining the allocation of resources.

The Company operates as a single segment which is development of the dermaportation drug delivery technology within Australia.

The Company is domiciled in Australia. All revenue from external parties is generated from Australia only. Segment revenues are allocated based on the country in which the party is located. Operating revenues of approximately Nil (31/12/2013 – Nil) are derived from a single external party.

All the assets are located in Australia only. Segment assets are allocated to countries based on where the assets are located.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (*continued*)

NOTE 6: CONTINGENT LIABILITIES

The directors of the Company are unaware of any existing contingent liabilities, other than the matter regarding the Company being served with a writ over a Convertible Note, as announced to the market.

NOTE 7: SHARE BASED PAYMENTS

On 28 November 2014, the following *performance rights* were granted to directors as part of their remuneration:

G Denison

- 5,000,000 performance rights to vest upon receipt by the Company of the first royalty payment resulting from a licence to a third party of the Company's powered Dermaportation technology (Milestone 1);
- 5,000,000 performance rights to vest upon the execution of a new licence agreement with a third party for the utilisation of the Company's ETP technology (Milestone 2); and
- 5,000,000 performance rights to vest upon the receipt by the Company of licensing fees in excess of \$20,000,000 (Milestone 3).

J D Edwards

- 5,000,000 performance rights to vest upon receipt by the Company of the first royalty payment resulting from a licence to a third party of the Company's powered Dermaportation technology (Milestone 1);
- 5,000,000 performance rights to vest upon the execution of a new licence agreement with a third party for the utilisation of the Company's ETP technology (Milestone 2); and
- 5,000,000 performance rights to vest upon the receipt by the Company of licensing fees in excess of \$20,000,000 (Milestone 3).

C J Quirk

- 5,000,000 performance rights to vest upon receipt by the Company of the first royalty payment resulting from a licence to a third party of the Company's powered Dermaportation technology (Milestone 1);
- 5,000,000 performance rights to vest upon the execution of a new licence agreement with a third party for the utilisation of the Company's ETP technology (Milestone 2); and
- 5,000,000 performance rights to vest upon the receipt by the Company of licensing fees in excess of \$20,000,000 (Milestone 3).

On 18 December 2014, the following *performance rights* were granted to various consultants and employees as part of their remuneration:

- 12,333,332 performance rights to vest upon receipt by the Company of the first royalty payment resulting from a licence to a third party of the Company's powered Dermaportation technology (Milestone 1);
- 12,333,334 performance rights to vest upon the execution of a new licence agreement with a third party for the utilisation of the Company's ETP technology (Milestone 2); and
- 12,333,334 performance rights to vest upon the receipt by the Company of licensing fees in excess of \$20,000,000 (Milestone 3).

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS *(continued)*

NOTE 7: SHARE BASED PAYMENTS *(continued)*

All the performance rights were issued for nil consideration and may be exercised for nil consideration upon the occurrence of the Performance Conditions. The performance rights shall expire on 28 November 2017. The fair value of the performance rights granted was independently valued.

The total share based payment expense for the half-year ended recognised in the statement of comprehensive income was \$109,027, with the balance of \$2,656,142 to be carried forward and proportioned over the period up until the expiry date of 28 November 2017.

NOTE 8: EVENTS SUBSEQUENT TO REPORTING DATE

Subsequent to the end of the half-year ended 31 December 2014, the following events had occurred:

- On 2 January 2015, 1,345,023 listed options were converted to shares at an issue price of \$0.01 per share.
- On 5 January 2015, 64,000 listed options were converted to shares at an issue price of \$0.01 per share

OBJ LIMITED
A.B.N. 72 056 482 636

DIRECTORS' DECLARATION

In the opinion of the directors:

- a) The financial statements and notes are in accordance with the Corporations Act 2001, including:
 - i) giving a true and fair view of the consolidated entity's financial position as at 31 December 2014 and of its performance for the half-year ended on that date; and
 - ii) complying with Australian Accounting Standards AASB 134: Interim Financial Reporting;
- b) there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the board of directors.



Glyn Denison
Director

Dated this 25th day of February 2015

**INDEPENDENT AUDITOR'S REVIEW REPORT
TO THE MEMBERS OF
OBJ LIMITED**

We have reviewed the accompanying half-year financial report of OBJ Limited, which comprises the statement of financial position as at 31 December 2014, and the statement of comprehensive income, statement of changes in equity and statement of cash flows for the half-year ended on that date, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration of the consolidated entity comprising the company and the entities it controlled at the half-year end or from time to time during the half-year.

Directors' Responsibility for the Half-Year Financial Report

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including: giving a true and fair view of the consolidated entity's financial position as at 31 December 2014 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*. As the auditor of OBJ Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independence


In conducting our review, we have complied with the independence requirements of the *Corporations Act 2001*. We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of OBJ Limited, would be in the same terms if given to the directors as at the time of this auditor's review report.

Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of OBJ Limited is not in accordance with the *Corporations Act 2001*, including:

- (a) giving a true and fair view of the consolidated entity's financial position as at 31 December 2014 and of its performance for the half-year ended on that date; and
- (b) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

RSM Bird Cameron Partners
RSM BIRD CAMERON PARTNERS



Perth, WA
Dated: 25 February 2015

J A KOMNINOS
Partner